Company Performance Metrics
- Stephen Gorgol: Chief Financial OfficerPast Role: BioVex, Chief Financial Officer , Treasurer and Secretary
- Howard L. Kaufman: President and Chief Executive OfficerPast Role: Immuneering, Head of Research and Development
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments. Systemic dosing of these potent immune stimulants is restricted due to widespread immune activation and toxicity. When cytokines are injected into tumor tissue, they localize specifically and persistently, causing intense hot spots of inflammation that activate an
anti-tumor immune response.
Ankyra used its Anchored Immunotherapy Platform to develop ANK-101, a stable complex of a modified IL-12 cytokine with aluminum hydroxide (Alhydrogel) to overcome the limitations of traditional cytokine therapeutics. Alhydrogel, an FDA-approved adjuvant for use in human and veterinary vaccines, acts as a scaffold to locally retain the potent activity of IL-12 after intratumoral administration, improving its therapeutic window.
Ankyra's mission is to optimize the impact of anchored immunotherapy to improve the lives of patients with cancer.
